US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

2.000 +0.070 (+3.63%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum ↗
Via Chartmill
News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Thursday's after hours session: top gainers and losers ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Inhibikase Posts Wider Loss in Q2 ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >